This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2009;302(2):133-134.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The National Institutes of Health (NIH) is launching a program that will shepherd drug candidates aimed at treating rare and neglected diseases through the most challenging phase of drug development.

The program, called Therapeutics for Rare and Neglected Diseases (TRND), marks the agency's largest foray into developing drugs. It will bring together expertise from various sectors of the NIH—including the Office of Rare Diseases Research (ORDR), the National Human Genome Research Institute, and the NIH Chemical Genomics Center (NCGC)—as well as expertise from outside researchers and organizations. TRND's focus will be moving candidate molecules through the preclinical phase of development and then licensing the candidates to other entities for further development.

Leishmaniasis, a disease spread by sand flies such as the one pictured above, may be among the rare or neglected diseases targeted by a new National Institutes of Health initiative. (Photo credit: James Gathany/CDC)

Rare diseases . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Traversing the Valley of Death: A Guide to Assessing Prospects for Translational Success
Coller and Califf
Sci Transl Med 2009;1:10cm9-10cm9.
FULL TEXT